X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Simufilam
Therapeutic Area: Neurology Product Name: PTI-125
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Cassava Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
Details:
Evonik to supply commercial quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AP-325
Therapeutic Area: Neurology Product Name: AP-325
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2020
Details:
The CURE study is a randomized, double-blind, placebo controlled, parallel group study to evaluate the efficacy and safety after repeated oral dosing of Algiax´ lead product AP-325.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Varoglutamstat
Therapeutic Area: Neurology Product Name: PQ912
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020
Details:
Vivoryon and the Alzheimer’s Disease Cooperative Study have developed a new trial design for Phase 2a Alzheimer’s trial in the US as a stage gate to Phase 2b. Vivoryon’s lead candidate, PQ912, got approval of the International Nonproprietary Name (INN), varoglutamstat.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
